Amanote Research
Register
Sign In
MA26.09 Lazertinib, a Third Generation EGFR-TKI, in Patients With EGFR-TKI-Resistant NSCLC: Updated Results of a Phase I/Ii Study
Journal of Thoracic Oncology
- United States
doi 10.1016/j.jtho.2018.08.544
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
October 1, 2018
Authors
B.C. Cho
J. Han
S. Kim
K. Lee
D. Kim
Y. Lee
G. Lee
J. Lee
E.K. Cho
J. Kim
S.S. Lee
Y.J. Min
J. Kim
S.W. Shin
H.R. Kim
M.H. Hong
J.S. Ahn
S. Kang
S. Kim
S.B. Jang
S. Choi
M. Ahn
Publisher
Elsevier BV
Related search
Third Generation EGFR TKI Landscape for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)
Expert Review of Anticancer Therapy
Oncology
Pharmacology
MA08.03 EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients With Brain Metastases: A Meta-Analysis
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Trastuzumab Emtansine Delays and Overcomes Resistance to the Third-Generation EGFR-TKI Osimertinib in NSCLC EGFR Mutated Cell Lines
Journal of Experimental and Clinical Cancer Research
Cancer Research
Oncology
Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
Molecular Cancer Therapeutics
Cancer Research
Oncology
Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC
Lung Cancer Management
Upfront Radiation Versus EGFR-TKI: Which Is the Best Approach for EGFR-mutated NSCLC Patients With Brain Metastasis?
Translational Cancer Research
Cancer Research
Oncology
Radiology
Nuclear Medicine
Imaging
Overcoming T790M Mutant Small Cell Lung Cancer With the Third-Generation EGFR-TKI Osimertinib
Thoracic Cancer
Medicine
Pulmonary
Respiratory Medicine
Oncology
P1.01-81 Phase 3 Study of Pemetrexed-Platinum With or Without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-16 Low Dose Apatinib Combined With EGFR-TKI in Treating Advanced NSCLC After First-Generation EGFR-TKIs Treatment Failure
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary